Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells

Cellular Immunology
Michael ReichTimo Burster

Abstract

As part of the endocytic antigen processing pathway, proteolytic cleavage of the invariant chain (Ii) is important for the generation of class II-associated invariant chain peptide (CLIP). CLIP remains associated with the major histocompatibility complex (MHC) class II molecule to prevent premature loading of antigenic peptides. Cysteine proteases, such as Cathepsin S (CatS), CatL, or CatV, play a pivotal role in the final stage of Ii degradation depending on the cell type studied. Less is known regarding the early stages of Ii processing. We therefore explored whether the serine protease CatG is involved in the initial step of Ii degradation in primary antigen presenting cells (APC), since the cathepsin distribution differs between primary APC and cell lines. While primary human B cells and dendritic cells (DC) do harbor CatG, this protease is absent in B-lymphoblastoid cells (BLC) or monocyte-derived DC generated in vitro. In addition, other proteases, such as CatC, CatL, and the asparagine endoprotease (AEP), are active in BLC and monocyte-derived DC. Here we demonstrate that CatG progressively degraded Ii in vitro resulting in several intermediates. However, pharmacological inhibition of CatG in primary B cells and DC did n...Continue Reading

References

May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·J DeussingJ A Villadangos
Oct 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·P Stumptner-CuveletteP Benaroch
May 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jacek BaniaPhilippe Pierre
Sep 27, 2005·Immunological Reviews·Colin WattsCathy X Moss
Dec 13, 2005·Current Opinion in Immunology·Harold A Chapman
Mar 2, 2006·Molecular and Cellular Biology·Chi-Hui TangHarold A Chapman
May 5, 2006·Tissue Antigens·T Zavasnik-Bergant, B Turk
Dec 13, 2006·Current Opinion in Immunology·Peter van Endert, José A Villadangos
Jan 6, 2007·Science·Diana DudziakMichel C Nussenzweig
Jul 10, 2007·Journal of Peptide Science : an Official Publication of the European Peptide Society·Ewa WieczerzakJerzy Ciarkowski
Oct 17, 2007·Biochemical and Biophysical Research Communications·Nousheen ZaidiHubert Kalbacher
Nov 28, 2008·Cellular Immunology·Christina StoeckleTimo Burster
Jul 29, 2009·European Journal of Immunology·Jeff D ColbertColin Watts
Aug 26, 2009·Scandinavian Journal of Immunology·O J B LandsverkT F Gregers
Nov 17, 2009·Molecular Immunology·Timo BursterElizabeth D Mellins
Dec 4, 2009·Immunology Letters·Michael ReichTimo Burster

❮ Previous
Next ❯

Citations

Jun 28, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrea FerranteMargaret J Castellini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.